Surveilling Middle-Risk Prostate Cancer: Cautionary Data

A new study published in the December 2016 issue of the Journal of Urology indicates that active surveillance (AS) may not be a recommended treatment option for men with intermediate-risk prostate cancer.

Active surveillance is a NICE recommended treatment option for many incidents of prostate cancer. And, despite earlier research finding no significant difference in progression- free survival in low- and intermediate-risk populations, the new study conducted by the Sunnybrooke Health Sciences Centre and University of Toronto, Ontario, Canada, is significant because it has found a patient’s Gleason score to be an important factor in his 15-year metastasis-free survival (MFS) rate.

This evidence suggests that patients with a Gleason score of 7 are likely to suffer greater adverse outcomes through active surveillance in comparison to those with a Gleason score of 6 or less, and recommends that "Active surveillance for patients with Gleason 7 disease should be offered only in the setting of a clinical study," according to Hima Bindu Musunuru, MD.

For the full editorial extract, click here

#activesurveillance #prostatecancer

Recent Posts
Search By Tags
No tags yet.
Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

Registered Address: The Coach House, Grenville Court, Britwell Road, Burnham, SL1 8DF

Company Registration No: 08252168

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black YouTube Icon